RMB 6 Billion Raw Material Pharmaceutical Company to Resume Trading Tomorrow

Today’s Focus[Sunflower: Plans to Acquire 100% Equity of High-End Semiconductor Materials Company Xipu Materials and Other Assets; Stock Resumes Trading]Sunflower (300111.SZ) announced that the company plans to acquire 100% equity of Zhangzhou Xipu Materials Technology Co., Ltd. and 40% equity of Zhejiang Beide Pharmaceuticals Co., Ltd. through a combination of share issuance and cash payments, while also raising supporting funds. The company’s stock will resume trading on September 22, 2025. Xipu Materials is primarily engaged in the research, development, manufacturing, and sales of high-end semiconductor materials. Its main products include semiconductor-grade ultra-high purity electronic specialty gases, silicon-based precursors, and metal-based precursors, which are widely used in key semiconductor manufacturing processes such as diffusion, etching, and thin-film deposition. Beide Pharmaceuticals, a holding subsidiary of Sunflower, focuses on the research, development, manufacturing, and sales of drugs in the anti-infective, cardiovascular, and digestive system categories.[Changfei Fiber Optics: On September 19, Draka Comteq B.V. Reduced its Stake by 5% of the Company’s H Shares via Block Trading]Yangtze Optical Fiber (601869.SH) announced that the information disclosure obligor, Draka Comteq B.V., sold 37,595,000 H-shares of the company via a block trade on the Hong Kong Stock Exchange on September 19, 2025, representing 5.00% of the total issued shares of the listed company. After this change in equity interest, Draka Comteq B.V. no longer holds any H-shares of the company.[Shanxi Xinghuo Liquor: Shareholder Huachuang Xinrui Plans to Reduce Holdings by up to 1.33% of the Company’s Shares]Shanxi Xinghuacun Fen Wine (600809.SH) announced that, according to the relevant cooperation agreement of Lianhe Fund, it faces an arrangement for the fund’s maturity and exit, necessitating the reduction of all indirectly held shares of the company. Therefore, Huachuang Xinxin, a shareholder holding over 5%, intends to reduce its holdings by up to 16.2 million shares (inclusive) via block trading, with the planned reduction ratio not exceeding 1.33%. This reduction plan will be implemented within three months (including the day when the three-month period expires) following 15 trading days after the public disclosure of this reduction plan.Shareholder Changes[Guanzhong Ecology: Planning Control Rights Change; Stock Suspended from Trading]Guanzhong Ecology (300948.SZ) announced that its controlling shareholder, Qingdao Guanzhong Investment Group Co., Ltd., along with its actual controllers Li Chunlin and Xu Jianping, are planning matters related to a change in the company’s control rights. This may result in changes to the company’s controlling shareholder and actual controllers. Upon application, trading of the company’s shares and convertible bonds will be suspended starting September 22, 2025. The suspension is expected to last no more than two trading days. During the suspension period, the conversion of the company’s convertible bonds will be paused.[Golden Emperor Shares: Plans to Acquire Controlling Stake in Uniprecision]Golden Emperor Shares (603270.SH) announced that the company plans to acquire a controlling stake in Guangzhou Uniprecision Co., Ltd. Upon completion of the acquisition, Uniprecision will become a subsidiary of the company. This transaction does not constitute a related-party transaction or a major asset restructuring. Uniprecision specializes in stamping products and has accumulated deep expertise in stamping technology, mature management experience, and high-quality customer resources over the years.Increase/Decrease & Repurchase[Global Printing: Shareholder Plans to Reduce Stake by Up to 1%]Global Printing (002799.SZ) announced that Hong Kong Original Stone International Limited, a shareholder of the company, plans to reduce its holdings by no more than 3,200,400 shares through centralized bidding, representing 1% of the company’s total share capital. The reduction period will commence 15 trading days after the announcement and last for three months. The reason for the reduction is the shareholder’s need for liquidity, and the shares being reduced are from those issued prior to the initial public offering.[Xiuzhou Shares: Shareholder Plans to Reduce Stake by Up to 1.06%]Xiuchang Co., Ltd. (300160.SZ) announced that Hong Kong Hengtai Technology Co., Ltd., a shareholder holding more than 5% of the company, along with its acting-in-concert parties Suqian Xinxing Investment Co., Ltd. and Lu Xiuchang, plan to reduce their combined holdings of the company’s shares by no more than 8,175,140 shares, representing 1.06% of the company’s total share capital, through centralized bidding or block trading within three months after 15 trading days from the date of this announcement. The reason for the reduction is due to their own funding needs. The methods of reduction include centralized bidding and block trading, and the price will be determined based on market prices.[Haitai Technology: Shareholders Plan to Reduce Combined Stake by 2.53%]Haitaike (301022.SZ) announced that Suzhou Xilin Phase III Venture Capital Enterprise (Limited Partnership) plans to reduce no more than 1,468,096 shares, representing 1.5276% of the company’s total share capital; shareholder Zhao Dongmei plans to reduce no more than 961,029 shares, accounting for 1.0000% of the company’s total share capital. The reduction period will be from September 25, 2025, to December 24, 2025, and the reduction methods will include centralized bidding or block trading.Operations & Performance[Brother Technology: Brother Pharmaceutical Receives Drug Registration Certificate for Iopamidol Injection]Brother Technology (002562.SZ) announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has recently received the ‘Drug Registration Certificate’ issued by the National Medical Products Administration, approving the marketing and sales of Iopamidol Injection within China. The drug is mainly used for cardiovascular angiography and features low viscosity and good safety.Stock Price Abnormal Fluctuation[Xingye Technology: The Company’s Current Production and Operation Are Normal, with No Significant Matters to Be Disclosed]Xingye Technology (002674.SZ) announced that the cumulative deviation of the closing price increase for two consecutive trading days on September 18 and September 19, 2025, exceeded 20%, which constitutes an abnormal fluctuation in stock trading. After verification, the information previously disclosed by the company does not require correction or supplementation; recent production and business operations are normal, and there has been no significant change in the internal or external oper